초록

Compositions and methods for treating dry age related macular degeneration (dry AMD) by administration to an intraocular location of an anti-neovascular agent (such as bevacizumab) in either a liquid or solid polymeric vehicle (or both), such as a biodegradable hyaluronic acid or PLGA (or PLA).

대표청구항 ▼

1. A method for delaying the progression of dry age related macular degeneration (“dry AMD”) to wet age related macular degeneration (“wet AMD”) in a patient, the method comprising the steps of: (a) selecting a patient having dry AMD in a first eye and wet AMD in a second eye,(b) preparing a biocomp

1. A method for delaying the progression of dry age related macular degeneration (“dry AMD”) to wet age related macular degeneration (“wet AMD”) in a patient, the method comprising the steps of: (a) selecting a patient having dry AMD in a first eye and wet AMD in a second eye,(b) preparing a biocompatible, sustained release drug delivery system comprising between about 5 μg and about 20 μg bevacizumab and a polymeric hyaluronic acid vehicle;(c) injecting the drug delivery system into the vitreous cavity of the first eye of the patient, and;(d) releasing from the drug delivery system an average of between about 14 nanograms to about 120 nanograms of the bevacizumab over a 24 hour period for a period of time between about 3 months and about 6 months, thereby preventing the progression of the dry AMD to wet AMD with the bevacizumab released from the drug delivery system. 2. The method of claim 1, wherein the drug delivery system has a viscosity of between about 130,000 cps and about 300,000 cps at a shear rate of about 0.1 second at about 25° C. 3. The method of claim 1, wherein the drug delivery system is injected using a 25 to 30 gauge syringe. 4. A method for delaying the progression of dry age related macular degeneration (“dry AMD”) to wet age related macular degeneration (“wet AMD”) in a patient, the method consisting essentially of: (a) preparing a biocompatible sustained release drug delivery system comprising between about 5 μg and about 20 μg bevacizumab and a polymeric hyaluronic acid vehicle,(b) using a 25 to 30 gauge syringe for injecting the drug delivery system into the vitreous cavity of the eye of a patient with dry AMD, wherein the other, non-injected eye of the patient has wet AMD, and;(c) releasing from the drug delivery system an average of between about 14nanograms to about 120 nanograms of the bevacizumab over a 24 hour period for a period of time between about 3 months and about 6 months, thereby treating the dry AMD and low doses of the bevacizumab released from the drug delivery system by preventing or delaying onset of retinal neovascularization in the dry AMD eye injected, wherein the drug delivery system has a viscosity of between about 130,000 cps and about 300,000 cps at a shear rate of about 0.1/second at about 25° C.